Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
Aileron Therapeutics, Inc. (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company pioneering the development of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Located in Boston, Massachusetts, Aileron is leading the front in peptide therapeutics, focusing on innovative treatments for severe diseases.
The company’s flagship product is ALRN-6924, a unique chemoprotective agent designed to reactivate p53-mediated tumor suppression. Currently under multiple clinical trials, ALRN-6924 targets both MDMX and MDM2 proteins, pivotal in restoring the p53 function, often referred to as the “guardian of the genome,” due to its significant role in cancer prevention.
Another promising candidate is LTI-03, a novel Caveolin-1-related peptide in development for treating idiopathic pulmonary fibrosis (IPF). It is in a Phase 1b clinical trial, with results expected in the second quarter of 2024. Additionally, LTI-01 is a proenzyme under clinical evaluation for treating loculated pleural effusions, having completed Phase 1b and Phase 2a trials.
In the wake of challenging results from a Phase 1b breast cancer trial of ALRN-6924, leading to its termination, Aileron has been exploring strategic alternatives to maximize shareholder value. Recently, the company acquired Lung Therapeutics, Inc., integrating a pipeline of therapies targeting orphan pulmonary diseases.
The company remains well-funded, following an $18 million acquisition-financing round, bolstering its financial stability to propel ongoing clinical trials and corporate initiatives. As Aileron transitions under new leadership, with Dr. Brian Windsor as CEO, it continues to prioritize advancing its therapeutic candidates toward commercialization.
Visit aileronrx.com for more information about their groundbreaking research and future developments.
Aileron Therapeutics (NASDAQ: ALRN) reported Q3 2024 financial results and highlights. The company announced positive data from Cohort 2 of its Phase 1b trial for LTI-03 in IPF patients, showing dose-dependent effects in five biomarkers. The combined data from Cohorts 1 and 2 achieved statistical significance in four biomarkers. Cash position was $17.7 million as of September 30, 2024, expected to fund operations into June 2025. Q3 net loss was $5.8 million ($0.27 per share), with R&D expenses at $3.7 million and G&A expenses at $2.3 million.
Aileron Therapeutics (NASDAQ: ALRN) announced positive topline data from Cohort 2 of its Phase 1b trial for LTI-03 in Idiopathic Pulmonary Fibrosis (IPF). The high-dose treatment (5 mg BID) showed positive trends in seven out of eight biomarkers, with four biomarkers achieving statistical significance in the combined Cohort 1 and 2 data. Surfactant protein D, an indicator of epithelial cell health, decreased by 5% after 14 days of treatment. The drug demonstrated dose-dependent effects in five biomarkers and was well-tolerated with no safety concerns. The company is now planning a Phase 2 clinical trial.
Aileron Therapeutics (NASDAQ: ALRN) and Advancium Health Network have entered into an exclusive option agreement for ALRN-6924, targeting retinoblastoma, a rare pediatric eye cancer. Advancium paid a non-refundable fee for the option to acquire ALRN-6924, with potential additional payments upon exercise. The drug selectively targets MDM2 and MDMX proteins to activate p53-mediated tumor suppression in cancer cells. Retinoblastoma affects approximately 300 cases in the US and 9,000 worldwide annually, primarily in children. ALRN-6924 has shown promising results in preclinical models, demonstrating anti-proliferative activity in RB cell lines and compatibility with intraocular injection.
Aileron Therapeutics (NASDAQ: ALRN) is presenting data from its Phase 1b clinical trial of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis. The trial's Cohort 1, evaluating low-dose LTI-03 (2.5 mg BID), showed positive trends in seven out of eight biomarkers, with three showing statistically significant improvements in collagen synthesis, inflammation, and fibrogenesis.
The company has also completed enrollment for Cohort 2, testing high-dose LTI-03 (5 mg BID), with topline data expected soon. Pre-clinical data using precision cut lung slices (PCLS) further supports LTI-03's potential effectiveness in IPF treatment. The ongoing Phase 1b trial aims to evaluate the safety and tolerability of LTI-03 in IPF patients over 14 days of treatment.
Aileron Therapeutics (NASDAQ: ALRN) has completed enrollment in Cohort 2 of its ongoing Phase 1b clinical trial evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF). The trial, which enrolled a total of 24 patients, aims to assess the safety and tolerability of LTI-03 in IPF patients after 14 days of treatment. Cohort 2 will evaluate a high-dose of LTI-03 (5 mg BID).
Previously announced results from Cohort 1, which evaluated a low-dose of LTI-03 (2.5 mg BID), showed positive trends in seven out of eight biomarkers. This suggests a potential therapeutic effect, with evidence of reduced expression among multiple profibrotic proteins produced by basal-like cells and fibroblasts that contribute to IPF progression. Three biomarkers showed statistically significant data, reinforcing LTI-03's potential to improve lung function and reverse IPF progression.
Aileron Therapeutics (NASDAQ: ALRN), a biopharmaceutical company focused on orphan pulmonary and fibrosis indications, has announced its participation in the 8th Annual IPF Summit in Boston, MA. Brian Windsor, Ph.D., President and CEO of Aileron, will present on August 21, 2024, at 2:45 PM ET.
The presentation, titled 'Biomarker Strategies in the Clinical Development of LTI-03 in IPF', will be part of the session on Emerging Biology & Early Translation. This session aims to enhance the predictive power of preclinical modeling and improve the transition from bench to bedside for next-generation therapeutics.
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key stakeholders from the biopharmaceutical industry, clinical practice, and academic research globally.
Aileron Therapeutics (NASDAQ: ALRN) reported Q2 2024 financial results and business highlights. Key points include:
1. Positive data from Cohort 1 of Phase 1b trial for LTI-03 in idiopathic pulmonary fibrosis (IPF), with positive trends in 7 of 8 biomarkers.
2. Completed a $18.2 million registered direct offering in May 2024.
3. Q2 2024 R&D expenses increased to $3.7 million from $0.2 million in Q2 2023.
4. G&A expenses rose to $5.3 million from $1.9 million year-over-year.
5. Net loss for Q2 2024 was $8.9 million ($0.45 per share).
6. Cash position as of June 30, 2024: $21.9 million, expected to fund operations into H2 2025.
7. Topline results from Cohort 2 (high-dose LTI-03) expected in Q3 2024.
Aileron Therapeutics (NASDAQ: ALRN), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis indications, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's President and CEO, Brian Windsor, Ph.D., is scheduled to present on Tuesday, August 13, 2024, at 4:00 p.m. EDT in Boston, MA.
Investors and interested parties can access a live webcast of the presentation through Aileron's investor relations website. The webcast replay will remain available for 90 days following the event, providing an opportunity for those unable to attend the live presentation to catch up on Aileron's latest developments and future plans.
Aileron Therapeutics (NASDAQ: ALRN), a biopharmaceutical company focusing on orphan pulmonary and fibrosis indications, announced that it will be included in the Russell Microcap® Index. This inclusion will take effect on July 1, 2024, following the annual reconstitution of Russell U.S. Indexes, which ranks the 4,000 largest U.S. stocks by market capitalization. Membership in the Russell Microcap® Index means automatic inclusion in applicable growth and value style indexes, and will last for one year.
Aileron's inclusion is attributed to the clinical progress of its lead asset, LTI-03, for idiopathic pulmonary fibrosis, with positive data from a Phase 1b trial. Russell indexes are benchmarks for about $10.5 trillion in assets and are widely used by investment managers and institutional investors.
Aileron Therapeutics (NASDAQ: ALRN) reported its Q1 2024 financial results, highlighting positive data from Cohort 1 of its Phase 1b trial for LTI-03 in idiopathic pulmonary fibrosis (IPF) patients. The trial showed statistical significance in three out of eight biomarkers, with promising safety and tolerability. Topline results from Cohort 2 are expected in Q3 2024. The company raised approximately $20 million from a direct offering in May 2024, potentially adding another $20 million from warrant exercises. Cash reserves were $12 million as of March 31, 2024, expected to fund operations into H2 2025. R&D expenses rose to $3.5 million from $1.8 million YoY, primarily due to the acquisition of Lung. G&A expenses increased to $3.7 million from $2.2 million. Net loss for the quarter was $7.1 million, compared to $4.8 million in Q1 2023.
FAQ
What is the current stock price of Aileron Therapeutics (ALRN)?
What is the market cap of Aileron Therapeutics (ALRN)?
What does Aileron Therapeutics specialize in?
What is ALRN-6924?
What recent strategic move did Aileron make?
Who is the new CEO of Aileron Therapeutics?
What is LTI-03, and its significance?
What are the financial prospects for Aileron?
What was the outcome of the ALRN-6924 breast cancer trial?
How is Aileron's intellectual property portfolio?
What are LTI-01's clinical achievements?
Where can one find more information about Aileron Therapeutics?
